| Citation: |
ZHENG Yabing, YU Yang, WANG Xiaojia. Hot Issues in Internal Medicine Treatment for HER2 Positive Early Breast Cancer Reflected in the 2019 St. Gallen International Breast Cancer Conference[J]. Cancer Research on Prevention and Treatment, 2019, 46(12): 1053-1056. DOI: 10.3971/j.issn.1000-8578.2019.19.1005
|
The 16th St. Gallen International Breast Cancer Conference was held in Vienna, Austria from March 20, 2019 to March 23, 2019. The biennial St. Gallen International Breast Cancer Conference and Expert Consensus present an inventory and summary of the progress of breast cancer treatment over the past two years. The theme of this conference is "assessing the clinical benefits of early breast cancer (EBC) treatment". The meeting mainly focused on the hot topics of surgical treatment, medical treatment and radiotherapy for early breast cancer, as well as controversial topics, and finally formed an expert consensus. The paper presents an overview of the hot issues (HER2 positive early breast cancer) reflected in this conference.
| [1] |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010, 375(971): 377-384. doi: 10.1016-S0140-6736(09)61964-4/
|
| [2] |
Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen[J]. Clin Cancer Res, 2007, 13(1): 228-233. doi: 10.1158/1078-0432.CCR-06-1345
|
| [3] |
Huober J, Holmes E, Baselga J, et al. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase Ⅲ neoadjuvant clinical trial in patients with HER2-positive primary breast cancer[J]. Eur J Cancer, 2019, 118: 169-177. doi: 10.1016/j.ejca.2019.04.038
|
| [4] |
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally adanced inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800. doi: 10.1016/S1470-2045(16)00163-7
|
| [5] |
Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phaseⅡTRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer[J]. Eur J Cancer, 2018, 89: 27-35. doi: 10.1016/j.ejca.2017.10.021
|
| [6] |
Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628. doi: 10.1056/NEJMoa1814017
|
| [7] |
Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study[J]. J Clin Oncol, 2014, 32(20): 2142-2150. doi: 10.1200/JCO.2013.53.1608
|
| [8] |
Bellon JR, Guo H, Barry WT, et al. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)[J]. Breast Cancer Res Treat, 2019, 176(2): 303-310. doi: 10.1007/s10549-019-05238-4
|
| [9] |
Von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131. doi: 10.1056/NEJMoa1703643
|
| [10] |
Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(3): 367-377. doi: 10.1016/S1470-2045(15)00551-3
|
| [11] |
Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(8): 741-748. doi: 10.1016/S1470-2045(13)70225-0
|
| [12] |
Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial[J]. Lancet Oncol, 2019, 393(10191): 2591-2598. doi: 10.1016/S0140-6736(19)30653-1
|
| [13] |
Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial[J]. Lancet Oncol, 2019, 393(10191): 2599-2612. doi: 10.1016/S0140-6736(19)30650-6
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: